Enanta Pharmaceuticals misses Q4 revenue estimates, posts wider net loss
Overview
US biotech firm's fiscal Q4 revenue missed analyst expectations
Net loss widened to $23.7 mln from $18.7 mln
Company cut workforce by about one-third in September to boost efficiency and extend cash runway
Outlook
Company expects topline data from LOTUS pediatric RSV trial in 1Q 2027
Topline data from RESOLVE adult RSV trial expected in 2027
Company expects cash and marketable securities to fund operations into fiscal 2029
Result Drivers
ROYALTY REVENUE DECLINE - Co said Q4 revenue decrease was due to lower royalties from AbbVie's sales of MAVYRET/MAVIRET
HIGHER R&D SPENDING - Co said Q4 R&D expenses rose due to increased clinical trial costs for RSV programs, driven by RESOLVE and LOTUS studies
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Miss | $12.87 mln | $14.20 mln (3 Analysts) |
Q4 Loss Per Share | $0.81 | ||
Q4 Net Loss | $23.72 mln | ||
Q4 Operating Expenses | $34.91 mln | ||
Q4 Operating Income | -$22.04 mln | ||
Q4 Pretax Loss | $23.75 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc is $20.00, about 82% above its November 13 closing price of $10.99
Reuters Recommended Reads
Nov 16 - ALX Oncology Q3 net loss per share narrows
Nov 16 - Moleculin Biotech Q3 net loss narrows as MIRACLE trial advances
Nov 16 - CNS Pharmaceuticals Q3 net loss narrows as R&D costs fall
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)